{"transactions":[{"id":4639638,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-13T21:13:17.000Z","date":"2026-10-12","kind":"grant","planned":false,"acquired":true,"shares":2283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":84156,"source":{"system":"sec-edgar","filing":"0001193125-26-420643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1916940/000119312526420643/ownership.xml","form_type":"4"}},{"id":711250,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-10T23:41:06.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":2789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":81873,"source":{"system":"sec-edgar","filing":"0001193125-26-301166","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526301166/ownership.xml","form_type":"4"}},{"id":810563,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-11T00:53:18.000Z","date":"2026-04-10","kind":"grant","planned":false,"acquired":true,"shares":3775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":79084,"source":{"system":"sec-edgar","filing":"0001193125-26-151628","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526151628/ownership.xml","form_type":"4"}},{"id":830960,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":830959,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":830958,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":830957,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":10362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":10362,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":830956,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.596,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":10665},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":830955,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:13:56.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":10665,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":10665,"derivative":{"exercise_price":3.91,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":10665},"source":{"system":"sec-edgar","filing":"0001193125-26-120230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120230/ownership.xml","form_type":"4"}},{"id":888258,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:29:59.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-064105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064105/ownership.xml","form_type":"4"}},{"id":939305,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T22:06:08.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":11560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":75309,"source":{"system":"sec-edgar","filing":"0001193125-26-013035","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526013035/ownership.xml","form_type":"4"}},{"id":1019389,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:06.000Z","date":"2025-10-10","kind":"grant","planned":false,"acquired":true,"shares":10367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":63749,"source":{"system":"sec-edgar","filing":"0001193125-25-238984","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312525238984/ownership.xml","form_type":"4"}},{"id":1088658,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T22:20:48.000Z","date":"2025-07-10","kind":"grant","planned":false,"acquired":true,"shares":11875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately."}],"balance_after":53382,"source":{"system":"sec-edgar","filing":"0000950170-25-095406","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025095406/ownership.xml","form_type":"4"}},{"id":1135577,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:51:47.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077036","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077036/ownership.xml","form_type":"4"}},{"id":1173381,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T20:55:55.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":9705,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":41507,"source":{"system":"sec-edgar","filing":"0000950170-25-053348","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025053348/ownership.xml","form_type":"4"}},{"id":1323009,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T23:38:58.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":8972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":31802,"source":{"system":"sec-edgar","filing":"0000950170-24-139797","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024139797/ownership.xml","form_type":"4"}},{"id":1472251,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:20:27.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076408","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076408/ownership.xml","form_type":"4"}},{"id":1860916,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T00:44:17.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015314/doc4.xml","form_type":"4"}},{"id":2270595,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":31008,"kind":"person","name":"Marks Gilbert Lynn","position":1,"cik":"0001916940","reported_name":"Marks Gilbert Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:11:11.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":10362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/12 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":10362,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":10362},"source":{"system":"sec-edgar","filing":"0000899243-22-018272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018272/doc4.xml","form_type":"4"}}]}